医学
内科学
髓样
流式细胞术
肿瘤科
髓性白血病
总体生存率
骨髓增生异常综合症
不利影响
胃肠病学
免疫学
骨髓
作者
Wei‐Ying Jen,Koji Sasaki,Sanam Loghavi,Sa A. Wang,Wei Qiao,Gautam Borthakur,Farhad Ravandi,Tapan M. Kadia,Ghayas C. Issa,Nicholas J. Short,Musa Yılmaz,Naval Daver,Courtney D. DiNardo
摘要
Targeted therapy development for acute myeloid leukaemia (AML) requires an understanding of specific expression profiles. We collected flow cytometry data on 901 AML patients and recorded aberrant CD7 expression on leukaemic blasts. 263 (29.2%) had blasts positive for CD7. CD7+ AML was more likely to be adverse risk (64.6% vs. 55.6%, p = 0.0074) and less likely to be favourable risk (15.2% vs. 24.1%, p = 0.0074) by European LeukemiaNet 2022 criteria. Overall survival was inferior (11.9 [95% CI, 9.7-15.9] vs. 19.0 months [95% CI, 16.1-23.0], p = 0.0174). At relapse, 30.4% lost and 19.0% gained CD7, suggesting moderate instability over time.
科研通智能强力驱动
Strongly Powered by AbleSci AI